Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Methyl 5-(4-fluorophenylsulfonyloxy)benzimidazole-2-carbamate
1. 90509-02-7
2. Luxabendazolum
3. Hoe 216v
4. Methyl 5-hydroxy-2-benzimidazolecarbamate, P-fluorobenzenesulfonate (ester)
5. Hoe-216v
6. 34s1s00gv3
7. Luxabendazol
8. Luxabendazol [spanish]
9. Luxabendazolum [latin]
10. Ccris 7645
11. Luxabendazole [inn:ban]
12. Unii-34s1s00gv3
13. [2-(methoxycarbonylamino)-3h-benzimidazol-5-yl] 4-fluorobenzenesulfonate
14. Luxabendazole [inn]
15. Schembl321908
16. Chembl2104764
17. Dtxsid00238189
18. Methyl 5-(4-fluorophenylsulfonyloxy)benzimidazole-2-carbamate
19. 2-benzimidazolecarbamate, 5-hydroxy-, P-fluorobenzenesulfoonate
20. Zinc1842766
21. Akos015901189
22. Akos015967126
23. 509l027
24. Luxabendazole, Vetranal(tm), Analytical Standard
25. J-505262
26. Q27256388
27. 2-((methoxycarbonyl)amino)-1h-benzo[d]imidazol-5-yl 4-fluorobenzenesulfonate
28. Benzenesulfonic Acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1h-benzimidazol-6-yl Ester
| Molecular Weight | 365.3 g/mol |
|---|---|
| Molecular Formula | C15H12FN3O5S |
| XLogP3 | 2.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 5 |
| Exact Mass | 365.04816983 g/mol |
| Monoisotopic Mass | 365.04816983 g/mol |
| Topological Polar Surface Area | 119 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 576 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A Luxabendazole manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Luxabendazole, including repackagers and relabelers. The FDA regulates Luxabendazole manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Luxabendazole API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Luxabendazole manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Luxabendazole supplier is an individual or a company that provides Luxabendazole active pharmaceutical ingredient (API) or Luxabendazole finished formulations upon request. The Luxabendazole suppliers may include Luxabendazole API manufacturers, exporters, distributors and traders.
click here to find a list of Luxabendazole suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Luxabendazole Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Luxabendazole GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Luxabendazole GMP manufacturer or Luxabendazole GMP API supplier for your needs.
A Luxabendazole CoA (Certificate of Analysis) is a formal document that attests to Luxabendazole's compliance with Luxabendazole specifications and serves as a tool for batch-level quality control.
Luxabendazole CoA mostly includes findings from lab analyses of a specific batch. For each Luxabendazole CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Luxabendazole may be tested according to a variety of international standards, such as European Pharmacopoeia (Luxabendazole EP), Luxabendazole JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Luxabendazole USP).
LOOKING FOR A SUPPLIER?
